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Introduction
In the context of a clinical trial, we observed a surprisingly
high methicillin resistant S. aureus (MRSA) eradication
rate of a placebo solution containing a cationic polymeric
compound (CPC). The most active compound altering
bacterial growth was identified by testing individually all
molecules entering the composition of the commercial
solution.
Objectives
To assess the inhibitory capacity of a decolonisation
solution and determine the in vitro time kill curves of
Prontoderm® (containing polyhexanide plus CPC) versus
CPC alone and versus a control solution containing only
excipients and emollients.
Methods
Minimal inhibitory concentrations (MIC) of all com-
pounds entering in the composition of a decolonization
solution were assessed by a macro-method in liquid
medium, on MRSA strains from the prevalent lineage
isolated in our institution. A constant and calibrated
inoculum of MRSA was exposed to adapted concentra-
tions (4-fold MIC) of inhibitory compounds in liquid
medium. Aliquots were sampled serially at time 15 to
240 min and diluted before plating on nutrient agar
medium. Survival cells were enumerated after 20 h incu-
bation at 37°C.
Results
In addition to polyhexanide, the decolonisation solution
contained another compound showing activity on
MRSA growth. Polyhexanide was rapidly bactericidal for
all tested MRSA strains; a rapid decrease of >5 logs in
15 min was generally observed. CPC showed also a sig-
nificant effect on MRSA development. The killing was
slower than that observed with polyhexanide but
reached 4 to 5 logs after 2 h exposure.
Conclusion
In addition to the active bactericidal compound, decolo-
nization solution contains additives altering bacterial
growth. The choice of a reliable placebo solution for
comparison purposes in clinical trials should be adapted.
Susceptibility of other relevant bacterial species, particu-
larly multi-resistant pathogens, to the CPC should be
evaluated.
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